Ruxolitinib ( DrugBank: Ruxolitinib )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 1 |
| 65 | Primary immunodeficiency | 1 |
| 228 | Bronchiolitis obliterans | 3 |
60. Aplastic anemia
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100051874 | 2021-10-01 | 2021-10-08 | Efficacy and safety of ruxolitinib in preventing aGVHD after haplotype bone marrow transplantation in severe aplastic anemia | Efficacy and safety of ruxolitinib in preventing aGVHD after haplotype bone marrow transplantation in severe aplastic anemia | Severe aplastic anemia | experimental group:ruxolitinib; | The Second Affiliated Hospital of Dalian Medical University | NULL | Recruiting | 1 | 60 | Both | experimental group:20; | N/A | China |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05398809 (ClinicalTrials.gov) | January 18, 2023 | 26/5/2022 | Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced);Alopecia Areata | Drug: Ruxolitinib | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Recruiting | 12 Years | 65 Years | All | 70 | Phase 2 | United States |
228. Bronchiolitis obliterans
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05413356 (ClinicalTrials.gov) | June 1, 2022 | 7/6/2022 | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation | Bronchiolitis Obliterans Syndrome;Hematologic Malignancy | Drug: Ruxolitinib | First Affiliated Hospital of Zhejiang University | Second Affiliated Hospital, School of Medicine, Zhejiang University;Zhejiang Provincial People's Hospital;The First Affiliated Hospital of Zhejiang Chinese Medical University;Sir Run Run Shaw Hospital;First Affiliated Hospital of Wenzhou Medical University;Ningbo No. 1 Hospital;The Affiliated People's Hospital of Ningbo University;Jinhua Central Hospital;Taizhou Hospital;Union hospital of Fujian Medical University;Xiangya Hospital of Central South University | Recruiting | 18 Years | 65 Years | All | 50 | Phase 2 | China |
| 2 | NCT04908735 (ClinicalTrials.gov) | November 12, 2021 | 26/5/2021 | Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant | Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study | Hematopoietic Stem Cell Transplant (HSCT);Bronchiolitis Obliterans (BO) | Drug: Ruxolitinib | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 5 Years | 25 Years | All | 40 | Phase 2 | United States |
| 3 | NCT03674047 (ClinicalTrials.gov) | April 19, 2019 | 14/9/2018 | Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | Other Cancer | Drug: ruxolitinib | Massachusetts General Hospital | Incyte Corporation | Recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | United States |